Kymera Therapeutics Stock Fundamentals
| KYMR Stock | USD 40.45 1.05 2.66% |
Kymera Therapeutics fundamentals help investors to digest information that contributes to Kymera Therapeutics' financial success or failures. It also enables traders to predict the movement of Kymera Stock. The fundamental analysis module provides a way to measure Kymera Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Kymera Therapeutics stock.
At this time, Kymera Therapeutics' Non Operating Income Net Other is relatively stable compared to the past year. Kymera | Select Account or Indicator |
Kymera Therapeutics Company Return On Asset Analysis
Kymera Therapeutics' Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Kymera Therapeutics Return On Asset | -0.15 |
Most of Kymera Therapeutics' fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Kymera Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Kymera Total Assets
Total Assets |
|
Based on the latest financial disclosure, Kymera Therapeutics has a Return On Asset of -0.1538. This is 98.24% lower than that of the Biotechnology sector and 99.35% lower than that of the Health Care industry. The return on asset for all United States stocks is 9.86% higher than that of the company.
Kymera Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Kymera Therapeutics's current stock value. Our valuation model uses many indicators to compare Kymera Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Kymera Therapeutics competition to find correlations between indicators driving Kymera Therapeutics's intrinsic value. More Info.Kymera Therapeutics is rated second overall in return on equity category among its peers. It is currently regarded as number one stock in return on asset category among its peers . At this time, Kymera Therapeutics' Return On Equity is relatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Kymera Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Kymera Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Kymera Therapeutics' direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Kymera Therapeutics could also be used in its relative valuation, which is a method of valuing Kymera Therapeutics by comparing valuation metrics of similar companies.Kymera Therapeutics is currently under evaluation in return on asset category among its peers.
Kymera Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Kymera Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Kymera Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Kymera Fundamentals
| Return On Equity | -0.26 | ||||
| Return On Asset | -0.15 | ||||
| Profit Margin | (1.91) % | ||||
| Operating Margin | (19.28) % | ||||
| Current Valuation | 2.16 B | ||||
| Shares Outstanding | 64.77 M | ||||
| Shares Owned By Insiders | 1.30 % | ||||
| Shares Owned By Institutions | 98.69 % | ||||
| Number Of Shares Shorted | 8.35 M | ||||
| Price To Book | 2.93 X | ||||
| Price To Sales | 29.92 X | ||||
| Revenue | 78.59 M | ||||
| Gross Profit | (133.84 M) | ||||
| EBITDA | (143.2 M) | ||||
| Net Income | (146.96 M) | ||||
| Cash And Equivalents | 392.31 M | ||||
| Cash Per Share | 7.61 X | ||||
| Total Debt | 84.67 M | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 4.60 X | ||||
| Book Value Per Share | 13.79 X | ||||
| Cash Flow From Operations | (102.83 M) | ||||
| Short Ratio | 15.84 X | ||||
| Earnings Per Share | (2.34) X | ||||
| Price To Earnings To Growth | 0.64 X | ||||
| Target Price | 58.84 | ||||
| Number Of Employees | 184 | ||||
| Beta | 2.22 | ||||
| Market Capitalization | 2.62 B | ||||
| Total Asset | 575.76 M | ||||
| Retained Earnings | (530.75 M) | ||||
| Working Capital | 319.63 M | ||||
| Net Asset | 575.76 M |
About Kymera Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Kymera Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kymera Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kymera Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 43.6 M | 73 M | |
| Total Revenue | 90.4 M | 94.9 M | |
| Cost Of Revenue | 217.4 M | 228.3 M | |
| Stock Based Compensation To Revenue | 0.49 | 0.35 | |
| Sales General And Administrative To Revenue | 0.81 | 1.19 | |
| Research And Ddevelopement To Revenue | 2.77 | 4.91 | |
| Capex To Revenue | 0.39 | 0.41 | |
| Revenue Per Share | 1.21 | 0.92 | |
| Ebit Per Revenue | (1.90) | (1.99) |
Pair Trading with Kymera Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Kymera Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Kymera Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Kymera Stock
Moving against Kymera Stock
The ability to find closely correlated positions to Kymera Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Kymera Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Kymera Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Kymera Therapeutics to buy it.
The correlation of Kymera Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Kymera Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Kymera Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Kymera Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Kymera Stock Analysis
When running Kymera Therapeutics' price analysis, check to measure Kymera Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kymera Therapeutics is operating at the current time. Most of Kymera Therapeutics' value examination focuses on studying past and present price action to predict the probability of Kymera Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kymera Therapeutics' price. Additionally, you may evaluate how the addition of Kymera Therapeutics to your portfolios can decrease your overall portfolio volatility.